Under the deal, MB Innovations will initially offer design and development expertise to support development of MicroPort’s portfolio of instruments and instrument systems associated with its Fast Recovery, tissue-sparing approach to hip arthroplasty procedures.
During the agreement period, additional development programmes will be started to develop other differentiated implants and instruments that are used for both hip and knee arthroplasty procedures.
MPO chief executive officer Ted Davis said: "Troy and his team have an established track record of innovation and product commercialisation. I’m looking forward to the impact they can have on our product offering.
"We have already identified the initial programmes that leverage MPO’s ongoing efforts at innovative, tissue friendly arthroplasty techniques.
"I am confident that MBI will accelerate the pace at which we execute on our mission of delivering important and highly differentiated technologies to help surgeons care for their patients."
In January 2014, MicroPort Scientific had completed the acquisition of Wright Medical’s OrthoRecon business.
MPO is poised to capitalise on the macro trends of increasing globalisation and expanding the OrthoRecon business in the fast-growing emerging market economies, with the help of its China-based global parent.
The new products will allow MPO to enable surgeons to offer tissue-sparing surgical procedures to their patients that result in less pain and a quicker recovery from joint replacement surgery.
Image: MicroPort corporate headquarters in China. Photo: courtesy of MicroPort Scientific Corporation.